Nothing said here yet.
to join the conversation.
REYKJAVIK, Iceland, Oct.
Enhanced process increases manufacturing productivity and frees up capacity to support growing demand across Alvotech’s biosimilars portfolio REYKJAVIK, Iceland and LONDON, UK (October 20, 2026) - Alvotech (NASDAQ: ALVO; ALVO-SDB), a global biotechnology…
Alvotech and Advanz Pharma previously submitted a European regulatory application for AVT29, a proposed biosimilar to Eylea 8 mg, as a line extension to the approved Mynzepli marketing authorization.
AVT29 submitted to the European Medicines Agency as a line extension to the existing marketing authorization for Mynzepli® (aflibercept 2 mg) High-dose aflibercept offers the potential to reduce treatment frequency for patients with retinal diseases…
LOTTE Biologics, a contract development and manufacturing (CDMO) organization, and Alvotech, a global biotechnology company specializing in the development and manufacture of biosimilar medicines for patients worldwide, announced today a long-term strategic…
Alvotech (NasdaqGM:ALVO) is back in focus after two closely timed manufacturing updates that reshape how its biosimilars could be supplied to major markets. Both moves revolve around capacity, regulatory readiness, and long term supply security.
Alvotech and LOTTE Biologics signing ceremony Alvotech and LOTTE Biologics signing ceremony to commemorate the formation of a strategic manufacturing agreement on October 6, 2026 Collaboration covers multiple biosimilar products to be manufactured at LOTTE…
Key TakeawaysAlvotech shares rose 13% after the FDA approved a second Reykjavik production suite for Simlandi, its Humira biosimilar, doubling the capacity available for U. S.
Investing.com -- Alvotech SA (NASDAQ:ALVO) shares jumped 13.5% Monday after the U.S. Food and Drug Administration approved a supplement to the Biologics License Application for AVT02, enabling the company to manufacture the drug substance in a second…
Approval enables AVT02 drug substance for U.S. commercial supply to be manufactured in either of Alvotech’s two Reykjavik drug substance suites Further confirms resolution of FDA inspection-related matters at the Reykjavik site REYKJAVIK, Iceland (October 5,…
Alvotech (NASDAQ:ALVO) shares gained 5. 6% in premarket trading after Barclays upgraded the biosimilar drug developer from Underweight to Overweight and raised its price target from $4.
REYKJAVIK, Iceland, August 31, 2026 - Alvotech (NASDAQ: ALVO; ALVO-SDB), a global biotechnology company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced that the U.S.